Our Science – Ho Website
Mitchell Ho, Ph.D.
| Q&A With Mitchell Ho, Ph.D. - Dr. Ho is a recipient of Ovarian Cancer Research Fund's Individual Investigator Award.|
| The NIH Antibody Interest Group (ABIG) - The monthly ABIG meetings are open to everyone interested.|
| BIOC301/302 - Biochemistry I/II - BIOC 301 and 302 are a comprehensive survey of biochemistry at the graduate level.|
| Understanding Mesothelioma By CURE Media Group - Q&A With Dr. Mitchell Ho, the recipient of the Mesothelioma Applied Research Foundation Craig Kozicki Memorial Grant|
| NCI/CCR: Novel Antibody Targets Glypican-3 in Liver Cancer - Scientists in the Ho lab generated a new human single-domain antibody, HN3, recognizes glypican-3 for liver cancer therapy. (NCI/CCR News. March 11, 2013)|
| Nature Reviews: The promise of new approaches in the management of hepatocellular carcinoma - "Mitchell Ho and colleagues investigated the potential of therapeutic antibodies for HCC." Nature Reviews Gastroenterology and Hepatology, Published online 26 March 2013|
| Nature SciBX: Glypican-3 (GPC3) - NCI patent application filed; available for licensing. Contact: Mitchell Ho, National Cancer Institute, Bethesda, Md. e-mail: email@example.com. SciBX 6(11); doi:10.1038/scibx.2013.262 Published online March 21 2013|
Dataset: Global Gene Expression Microarray for 2D and 3D Cultures of NCI-H226
- Gene expression microarray datasets from the NCI-H226 mesothelioma cell line: 2D and 3D cell cultures.
| Dr Mitchell Ho's talk at 2013 AACR Annual Meeting - Immune-based therapies targeting mesothelin and MUC16/CA125 (video and slides)|
| Breast Cancer Startup Challenge - The Challenge features inventions conceived and developed by scientists at the National Cancer Institute and Avon Foundation grantees to accelerate cancer therapy. Our antibody technology is one of ten inventions chosen for the Challenge.|
| Single-Domain Antibodies - Interview with Dr. Mitchell Ho, Genetic Engineering & Biotechnology News (Vol.33, No. 16; Sept 15, 2013)|
This page was last updated on 9/19/2013.